Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares were down 0.9% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.10. Approximately 2,842 shares changed hands during trading, a decline of 98% from the average daily volume of 131,842 shares. The stock had previously closed at $1.11.
Wall Street Analyst Weigh In
A number of analysts recently commented on TALS shares. Morgan Stanley dropped their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They issued a "buy" rating and a $18.00 target price for the company.
Get
Talaris Therapeutics alerts:
Talaris Therapeutics Stock Down 0.9 %
The firm has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $3.24. The stock has a market capitalization of $45.90 million, a P/E ratio of -0.66 and a beta of 1.89.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Sell-side analysts anticipate that Talaris Therapeutics, Inc. will post -1.86 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Talaris Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. increased its holdings in shares of Talaris Therapeutics by 163.0% in the 3rd quarter. Values First Advisors Inc. now owns 30,715 shares of the company's stock worth $81,000 after purchasing an additional 19,038 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in Talaris Therapeutics in the 3rd quarter worth about $64,000. Two Sigma Investments LP purchased a new position in Talaris Therapeutics in the 3rd quarter worth about $93,000. Bank of New York Mellon Corp lifted its stake in Talaris Therapeutics by 12.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 65,806 shares of the company's stock valued at $173,000 after acquiring an additional 7,112 shares during the period. Finally, Caas Capital Management LP purchased a new stake in shares of Talaris Therapeutics during the 3rd quarter valued at about $783,000. 65.43% of the stock is owned by institutional investors.
About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Further Reading
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
